InnoCare Pharma Ltd (688428)

Currency in CNY
28.45
+0.07(+0.25%)
Delayed Data·
688428 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
27.5429.16
52 wk Range
12.1434.02
Key Statistics
Bid/Ask
28.44 / 28.45
Prev. Close
28.38
Open
28.35
Day's Range
27.54-29.16
52 wk Range
12.14-34.02
Volume
12.49M
Average Volume (3m)
11.89M
1-Year Change
38.3942%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
688428 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins

InnoCare Pharma Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. It also developing ICP-B02 to treat CD20+B-cell malignancies; ICP-B05 to treat hemato-oncology; ICP-248 to treat chronic lymphocytic leukemia; ICP-332 to treat atopic dermatitis; ICP-488 to treat psoriasis; ICP-538 to treat autoimmune diseases; zurletrectinib (ICP-723) to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-189 to treat non-small cell lung cancer; and ICP-B05 to treat solid tumor. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.

Employees
1176
Market
China

InnoCare Pharma Ltd Earnings Call Summary for Q4/2025

  • InnoCare Pharma achieved first full-year profitability in 2025 with net profit of RMB 644M and diluted EPS of RMB 0.38, two years ahead of schedule.
  • Revenue surged 135% YoY to RMB 2.37-2.38B, driven by product sales of RMB 1.44B (up 43%) and successful business development transactions.
  • Company maintains strong cash position of RMB 2.8B in cash and equivalents to support R&D investments and globalization initiatives through 2026.
  • Despite 2025 profitability, EPS forecasts for FY2025-FY2026 remain negative at -0.02 USD amid continued strategic R&D pipeline investments.
  • Stock declined 0.61% to 24.46 post-earnings but delivered 44% return over past year; InvestingPro analysis indicates current overvaluation concerns.
Last Updated: 2026-03-25, 01:54 p/m
Read Full Transcript

Compare 688428 to Peers and Sector

Metrics to compare
688428
Peers
Sector
Relationship
P/E Ratio
39.1x−16.7x−0.4x
PEG Ratio
0.370.050.00
Price/Book
3.3x6.1x2.6x
Price / LTM Sales
10.6x13.3x3.2x
Upside (Analyst Target)
-34.4%46.7%
Fair Value Upside
Unlock4.3%7.6%Unlock
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Apr 23, 2026
EPS / Forecast
0.06 / --
Revenue / Forecast
528.63M / --
EPS Revisions
Last 90 days

688428 Income Statement

FAQ

What Is the InnoCare Pharma (688428) Stock Price Today?

The InnoCare Pharma stock price today is 28.45 CNY.

What Stock Exchange Does InnoCare Pharma Trade On?

InnoCare Pharma is listed and trades on the Shanghai Stock Exchange.

What Is the Stock Symbol for InnoCare Pharma?

The stock symbol for InnoCare Pharma is "688428."

What Is the InnoCare Pharma Market Cap?

As of today, InnoCare Pharma market cap is 25.16B CNY.

What Is InnoCare Pharma's Earnings Per Share (TTM)?

The InnoCare Pharma EPS (TTM) is 0.38.

When Is the Next InnoCare Pharma Earnings Date?

InnoCare Pharma will release its next earnings report on Apr 23, 2026.

From a Technical Analysis Perspective, Is 688428 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has InnoCare Pharma Stock Split?

InnoCare Pharma has split 0 times.

How Many Employees Does InnoCare Pharma Have?

InnoCare Pharma has 1176 employees.

What is the current trading status of InnoCare Pharma (688428)?

As of Apr 24, 2026, InnoCare Pharma (688428) is trading at a price of 28.45 CNY, with a previous close of 28.38 CNY. The stock has fluctuated within a day range of 27.54 CNY to 29.16 CNY, while its 52-week range spans from 12.14 CNY to 34.02 CNY.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.